A1: Preparation and periodic review of nation drug list.|
A2: Forming the formulary committee to modify unnecessary drugs from list.
A3: Improving drug shortage monitoring department in IFDA.
A4: Formulating drug and raw material registration processes based on health system priorities.
A5: Developing the protocols for each part of SC.
A6: Legislation for information sharing in SC.
A7: Prosecution of the companies causing drug shortage due to not notifying on time.
A8: Monitoring the punishments for illegal drug import and export.
A9: Clarifying and stabilizing rules and procedures.
A10: Technical and qualitative monitoring of production lines to prevent a sudden stop in production.
A11: Prioritize supporting the entry of raw materials and essential drugs, according to the list of essential drugs.|
A12: Using different competitive pricing for imported drugs.
A13: Reinforcement of cooperation and coordination with other relevant organizations.
A14: Planning for producing the raw material and finished products imported based on SC information.|
A15: Pharmaceutical companies’ timely notification to the IFDA about the recall or problems in production and import of products.
A16: Creating a competitive environment for imports.
A17: Restructuring emergency pharmaceutical companies to meet the real needs of pharmaceutical market.
A18: Establishment of an integrated and capillary distribution system based on supply chain information.
A19: Improving the delivery system to the remote areas.
A20: Using track and trace system.
A21: Encouraging patients to use alternative drugs available in the drug shortage by physicians.
A22: Commitment of physicians to prescribe drugs based on national formulary.
A23: Physicians should be up to date and alert about the availability of the drugs in market and the alternatives of medicines in shortage.
A24: Creating an integrated supply chain information system to manage medicines inventory.|
A25: Creating and using the databases to predict the shortage of medicines.
A26: Taking out the OTC drugs from insurance coverage and allocate their budget to essential drugs.|
A27: Preparing alternative medicine list by the expert committee for crisis condition.
A28: Reducing medicine waste by promoting rational use.
A29: Saving the strategic supply of essential medicines and keeping them up to date in macro level.
A30: Managing the allocation of drugs based on diseases priority in times of crisis.
A31: Adopting policies to build partnerships between all components of the supply chain and health services for the establishment of an integrated management.
A32: Recording strategies taken for drug shortage management and the reasons for their success or failure for use in future events.
A33: Adopting policies to increase the competitiveness of domestic pharmaceutical industry.
A34: Adopting policies to prevent the black market and drugs smuggling.
A35: Creating pharmaceutical industry think-tank to predict the effects of various economic and political factors on the pharmaceutical market.
A36: Actual value-based pricing and improving insurance coverage.
A37: Decreasing the effect of governmental authority in the field of production and import of medicine